

05-27-05

IFW



Please type a plus sign (+) inside this box → ☒

PTO/SB/21 (08-03)

Approved for use through 08/30/03. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

7

Application Number

10/714,111

Filing Date

November 14, 2003

First Named Inventor

Charles D. Claude

Group Art Unit

1711

Examiner Name

Jeffrey C. Mullis

Attorney Docket Number

50623.337

ENCLOSURES (check all that apply)

- ☒ Deposit Account 07-1850 Authorization
- ☒ Postage Paid Return Postcard
- ☒ Response to Restriction Requirement (3 pages) (in duplicate)
- ☐ Amendment Transmittal Letter (in duplicate)

☐ Affidavits/declaration(s)

☐ Petition for Extension of Time (___ months) (in duplicate)

☐ Information Disclosure Statement (in duplicate) with Form PTO-1449 and ___ References

☒ Express Mail Label No. EV 337978036 US

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s) In/Formal ___ Sheets with Submission of Drawings Transmittal
- ☐ Issue Fee Transmittal with PTO-85b (in duplicate)
- ☐ Request for Continued Examination Transmittal (RCE)
- ☐ Fee Transmittal Form (in duplicate)

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) _____

☐ After Allowance Communication to Group

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Request for Status of Application

☐ Other Enclosure(s) (please identify below):

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Squire, Sanders & Dempsey L.L.P.
Zhaoyang Li, Reg. No. 46,872

Signature

Date

May 25, 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: May 25, 2005

Typed or printed name

Rebecca M. Klits

Signature

Rebecca M. Klits

Date

May 25, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application Of:

Examiner: Jeffrey C. Mullis

Charles D. Claude

Art Unit: 1711

Serial No: 10/714,111

Filed: November 14, 2003

For: BLOCK COPOLYMERS OF
ACRYLATES AND
METHACRYLATES WITH
FLUOROALKENES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Examiner Mullis:

This communication is in response to the restriction requirement mailed on May 3, 2005.

The restriction requirement restricted claims 1-40 into four groups of claims: Group I, claims 1-15; Group II, claims 16-30; Group III, claims 31-35; and Group IV, claims 36-40. Applicants elect Group II claims, Claims 16-30, drawn to a medical device formed of a block copolymer that contains a fluorinated block and at least one non-fluorinated block.

Applicants elect the copolymer of claim 1 where R_1 is $\text{COOCH}_2\text{CH}_2\text{OH}$ and R_2 is H as the species of block copolymer for examination. Claims 16-19, 21-24 and 26-29 are all readable upon this copolymer.

Applicants elect antiproliferative as the species of agent for examination. An example of antiproliferative is 40-O-(2-hydroxy)ethyl-rapamycin (everolimus). Claims 21-30 are all readable upon antiproliferative as the elected bioactive agent.

Applicants further elect stent as the species of medical device for examination. Claims 16-30 are all readable upon stent as the elected medical device.

This election is being made without traverse, and Applicants reserve the right to filing of divisional applications.


The undersigned authorizes the examiner to charge any fees that may be required or credit of any overpayment to be made to Deposit Account No. 07-1850.

Should the Examiner have any questions regarding this communication, the Examiner is invited to contact the undersigned at the telephone number shown below.

Date: May 25, 2005

Squire, Sanders & Dempsey L.L.P.
One Maritime Plaza, Suite 300
San Francisco, CA 94111
Telephone (415) 954-0200
Facsimile (415) 393-9887

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'Zhaoyang Li', written over a horizontal line.

Zhaoyang Li, Ph.D.
Attorney for Applicant
Reg. No. 46,872